InSightec completes additional financing round of $30.9 million

       InSightec completes additional financing round of $30.9 million

--Board of Directors appoints James Davis as new CEO, Tom Gentile appointed as
Chairman of Board--

PR Newswire

TIRAT CARMEL, Israel, Dec. 9, 2012

TIRAT CARMEL, Israel, Dec.9, 2012 /PRNewswire/ --InSightec Ltd. announced
that it has completed its Series C financing totaling $30.9 million. In
parallel, the Board of Directors has appointed Mr. James (Jim) Davis as the
new Chief Executive Officer. Mr. Tom Gentile, President and CEO of GE
Healthcare Systems, has been appointed Chairman of the Board of Directors.Dr.
Jackob (Kobi) Vortman, who has founded and shepherded the company since its
inception, will continue his role as President and also step into a newly
created role of Chief Technology Officer, responsible for R&D, Regulatory
Affairs and Operations.

Jim Davis joins InSightec after 11 years with GE Healthcare.Jim was Vice
President & General Manager of the MRI business for 5 years, and also served
as VP & GM of the US Diagnostic Imaging Commercial Organization for 3 years.
Prior to that Jim worked in GE Aviation for 10 years. Jim also spent 4 years
with McKinsey & Co., a global management consulting firm. He has also been a
Director of InSightec for the past 3 years.

"I am delighted to be joining InSightec at this critical juncture. With our
2^nd FDA approval for pain palliation of bone metastases and CE marking for
neurological disorders now in hand, the future is extremely bright for
patients and for InSightec," said Mr. Davis. "InSightec has pioneered an
entirely new industry around a breakthrough therapy platform that uses MRI to
guide and control high intensity ultrasound waves to ablate tissue.ExAblate
offers patients a completely safe and non-invasive therapeutic option to
traditional surgery, minimally invasive therapies or radiation. This option
not only provides patients with shorter recovery times, but lowers the cost of
care at a time when healthcare systems around the globe are under tremendous
stress. The new investment will allow us to expand our global reach as well as
continuing research and development and clinical studies."

Dr. Vortman added: "We are very happy to welcome Jim on board. He has
contributed greatly to the company as a member of the Board of Directors, and
we believe that he brings unique knowledge of the medical market, a deep
understanding of the global marketplace, experience in international business,
plus commercial, clinical and technical skills to help InSightec achieve
widespread awareness and clinical adoption of this technology."

The Series C financing round includes an investment of $27.6 million by GE
Healthcare and $3.3 million by other investors.

"With this additional investment GE and the other investors have renewed their
longstanding commitment to the future of InSightec and focused ultrasound
technology," said Tom Gentile, InSightec's new chairman of the board."
InSightec continues to demonstrate its leadership and ability to deliver
clinically proven, safe and effective therapy systems and creating
non-invasive acoustical surgery centers used by multi-disciplinary groups of
physicians for multiple clinical disorders."

InSightec will open US commercial offices in Southeastern Wisconsin, where Jim
Davis will be located. The R&D and Operations teams will continue to operate
in Israel.

InSightec Ltd. is privately held by Elbit Imaging, General Electric, and
MediTech Advisors. Founded in 1999 InSightec developed ExAblate to transform
MR-guided Focused Ultrasound (MRgFUS) into a clinically viable technology.
ExAblate has won several awards for innovation and its potential to help
mankind including The Wall Street Journal Technology Innovation Awards and the
European Union's IST grand prize. TIME magazine recently named Focused
Ultrasound as "one of 50 best inventions". For more information please visit:

Media contact:

Lynn Golumbic
011 972 4 813 1380

SOURCE InSightec Ltd.

Press spacebar to pause and continue. Press esc to stop.